At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
CEP-18770 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy of CEP-18770 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted May 6, 2011·Updated Jun 28, 2023
In Brief
A Phase 2 clinical trial evaluating CEP-18770, Lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 11 participants across 8 sites in 2 countries.
Detailed Summary
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesNew Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartAug 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedMay 6, 2011
Enrollment StartAug 3, 2011
Primary CompletionMar 14, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.2 years ago
Interventions
CEP-18770drug
CEP-18770 will be administered per dose and schedule specified in the arm description.
Lenalidomidedrug
Lenalidomide will be administered per dose and schedule specified in the arm description.
Dexamethasonedrug
Dexamethasone will be administered per dose and schedule specified in the arm description.